ReviewNature reviews. Nephrology2026
Potassium and the kidney.
Review in Nature reviews. Nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The kidney distal tubule potassium switch, modern diet and hypertension.Nature reviews. Nephrology · 2026Review
- Fruits, Vegetables, and Legumes: Harnessing the Gut-Kidney Axis in Hypertensive Chronic Kidney Disease.Foods (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In the past decade, understanding of the mechanisms by which the kidneys sense dietary potassium imbalance and affect the cardiorenal system has substantially advanced. These mechanisms explain why low-potassium diets promote salt-sensitive hypertension, whereas potassium-rich diets enhance natriuresis and lower blood pressure. Increasing dietary potassium may therefore be an effective strategy to reduce cardiovascular disease risk. Clinical trials have shown that replacing regular salt with potassium-enriched substitutes lowers blood pressure and reduces cardiovascular events and mortality. Emerging evidence suggests that low dietary potassium intake contributes to kidney injury, and low urinary potassium excretion is associated with accelerated chronic kidney disease (CKD) progression. However, whether the cardiorenal benefits of adequate potassium intake in CKD outweigh the risk of hyperkalaemia remains uncertain. A clearer understanding of the relationship between dietary potassium intake and blood potassium levels, as well as the optimal blood potassium range for kidney and cardiovascular health, is needed to resolve this question. New strategies to mitigate hyperkalaemia, including use of potassium binders and various kidney-protective drugs, could enable people with CKD to safely consume a potassium-rich diet and avoid the need to discontinue use of medications that increase the risk of hyperkalaemia, such as renin-angiotensin-aldosterone inhibitors and mineralocorticoid receptor antagonists.
Indexed as
Identifiers
41611896What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.